Company news
Everest Medicines Ltd. (HKEX:1952) news
Everest Medicines Ltd. news releases on 6ix. Latest, Jun 6, 2025: NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
Press releases — page 2
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
June 6, 2025
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
May 22, 2025
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression
May 6, 2025
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
April 29, 2025
Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025
April 27, 2025
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
April 21, 2025
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
March 25, 2025
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
March 23, 2025
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
March 6, 2025
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
February 28, 2025
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
February 25, 2025
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
February 25, 2025
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
January 2, 2025
Everest Medicines Announces the Implementation of NEFECON NRDL Pricing in China
January 2, 2025
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
December 19, 2024
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
December 4, 2024